Find an Article

Filter articles

Applied Filters

Showing 141 to 150 of 279 results

LSIPR 50 2016: Xi Jinping and George Freeman

China, UK05-10-2016

Xi Jinping and George Freeman were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Jinping and Freeman were featured in the government and policy section, as LSIPR reports.

Preview: Life Sciences IP Summit 2016

EU16-09-2016Sarah Porch

Ahead of the Life Sciences IP Summit 2016 from October 20 to 21 at the Hilton London Paddington Hotel, Sarah Porch of C5 previews the main talking points, including Brexit and the UPC.

A bright future for biologics in Thailand

Thailand08-09-2016Alan Adcock and Atthachai Homhuan

An increasing number of biologics and biosimilar products are appearing in the Thai market, but there are challenges concerning IP protection and regulation, say Alan Adcock and Atthachai Homhuan of Tilleke & Gibbins.

Biomedical patents: the quest for balance

US18-08-2016Pat Carson and Mira Atanassova Mulvaney

The US Supreme Court’s Mayo and Myriad decisions have brought challenges to subject matter eligibility to the forefront in the biomedical industry, but they do not signal the end of biomedical patents. Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.

A state of flux: life sciences law in Australia

Australia16-08-2016Grant Shoebridge

In Australia, laws governing the patentability of inventions directed to gene-based technology, including isolated naturally occurring and artificial gene sequences, are contentious. Unlike the US situation, the law on patentability of inventions involving “principles of nature” in Australia has yet to be considered judicially, but that is about to change, says Grant Shoebridge of Shelston IP.

Easing the path for green tech in India

India11-08-2016Swarup Kumar and Jitesh Kumar

Even if India moves towards a patent-unfriendly environment for green technologies, the pro-patent and pro-environment lobbies can coexist and meet their respective goals, argue Swarup Kumar and Jitesh Kumar of Remfry & Sagar.

China v US: what can be patented in the life sciences field?

China, US09-08-2016Yu Guo

The US and China take very different approaches to the patentability of a range of inventions in the life sciences field, as Yu Guo of China Patent Agent reports.

IPR: five tips for successfully challenging Orange Book patents

US04-08-2016Mark Remus

Inter-partes reviews (IPRs) can be a powerful weapon against patents listed in the Orange Book. However, IPR practice favours a petitioner who has carefully thought about the issues and crafted the best strategy, says Mark Remus of Brinks Gilson & Lione.

Under surveillance: generic and biosimilar MAs

EU26-07-2016Ruth Franken

In order to be well prepared before a generic or biosimilar marketing authorisation is approved, drugs companies in the EU may consider monitoring pending applications, says Ruth Franken of Hogan Lovells.

Running an efficient clinical drug trial

International19-07-2016Charlie Nicholson

Everyone benefits from an efficiently run clinical drug study, including sponsors, contract research organisations, the investigator sites where patients are treated and observed, and most of all, patients, says Charlie Nicholson of Premier Research.

Showing 141 to 150 of 279 results